Patients with a variety of cancers spent much more money out of their own pocket than those in traditional plans. Some may be delaying treatment due to higher costs.
Cancer patients with high deductible health plans face significantly higher out-of-pocket costs that may be driving treatment decisions, a new study found.
The study, published in Jama Network Open Wednesday morning, examined more than 134,000 cancer patients between 2008 and 2018.
High deductible health plans “offer poorer protection than traditional insurance against unexpected health care expenses,” the authors of the study wrote.
As cancer care grows more expensive, more research should be done to examine the consequences of people delaying or abandoning treatment as a result of higher enrollment in high deductible health plans.
“Overall, our findings support previous studies that patients with cancer are subject to high financial burdens that may be associated with their clinical decision-making,” the authors wrote.
This study differs from previous research on healthcare costs among cancer patients in one significant aspect, the authors said. They wrote that to the best of their knowledge, this is the first time researchers used actual claims data to compare out-of-pocket costs among a large group of cancer patients with private insurance. Previous studies relied on cost estimates or patients’ reporting their own expenses.
Nationwide, 61% of American adults are covered through private health insurance. High deductible health plans are gaining more prevalence. Among those with private insurance, 30% had high deductible plans in 2019, up from 4% in 2006, the authors noted.
With high deductible health plans, consumers typically pay lower premiums, but they also have to pay more costs on their own before the insurance company starts paying. Theoretically, high deductible health plans are supposed to spur consumers to make better decisions about their health.
In reality, consumers with those plans delay treatment or hold off on preventive measures to protect their health, such as cancer screenings, the authors wrote.
The study found cancer patients with high deductible plans paid much more out of their own pocket than those with traditional insurance plans. The findings were especially stark among those diagnosed with breast cancer.
One year after diagnosis, breast cancer patients with high deductible plans paid $1,975 out of their own pocket. Cancer patients in traditional plans paid $160, the study found.
In addition, colorectal cancer patients in high deductible plans paid $865 more than those in traditional insurance plans during the month of diagnosis. Those with lung cancer in high deductible plans paid $655 per month more than those in traditional plans during the month of diagnosis.
The study also examined differences in costs among consumers without cancer. Consumers with high deductible plans paid a median of $63 per month in out-of-pocket costs, while those in traditional plans paid $30 per month.
The researchers also compared out-of-pockets costs among cancer patients with high deductible plans and those without cancer in traditional insurance plans. The differences were striking: those with breast cancer paid $1,683 more, while colorectal cancer patients paid $1,420 more out of their own pocket.
Those paying more out of pocket in high deductible plans are potentially suffering significant financial consequences, the authors note. They point to previous surveys indicating a majority of Americans couldn’t cover $1,000 in unexpected costs with their savings accounts.
The authors said more research should be done to examine clinical outcomes for those in high deductible plans.
“Financially vulnerable patients and their families continue to face painful decisions about whether to undergo high-cost cancer treatment or to delay or forego care,” the authors wrote.
Researchers at Stanford University, the Department of Veterans Affairs, and the Mayo Clinic produced the study.
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Verastem Begins Submission for Ovarian Cancer Combination
May 24th 2024Verastem is studying the combination of avutometinib and defactinib to treat low-grade serous ovarian cancer in patients with KRAS-mutations. The company plans to complete the new drug application in the second half of this year.
Read More